These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

29 related articles for article (PubMed ID: 9096705)

  • 1. Prolonged subcutaneous administration of recombinant alpha 2b interferon in patients with previously untreated Philadelphia chromosome-positive chronic-phase chronic myelogenous leukemia: effect on remission duration and survival: Cancer and Leukemia Group B study 8583.
    Ozer H; George SL; Schiffer CA; Rao K; Rao PN; Wurster-Hill DH; Arthur DD; Powell B; Gottlieb A; Peterson BA; Rai K; Testa JR; LeBeau M; Tantravahi R; Bloomfield CD
    Blood; 1993 Nov; 82(10):2975-84. PubMed ID: 8219189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UK Medical Research Council randomised, multicentre trial of interferon-alpha n1 for chronic myeloid leukaemia: improved survival irrespective of cytogenetic response. The UK Medical Research Council's Working Parties for Therapeutic Trials in Adult Leukaemia.
    Allan NC; Richards SM; Shepherd PC
    Lancet; 1995 Jun; 345(8962):1392-7. PubMed ID: 7760609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Durable molecular complete remission induced by low-dose imatinib plus low-dose interferon alpha in a patient with chronic myelogenous leukaemia.
    Takeuchi J; Miura K; Hatta Y; Sawada U
    J Int Med Res; 2006; 34(1):103-8. PubMed ID: 16604830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BCR-ABL-positive progenitors in chronic myeloid leukaemia patients in complete cytogenetic remission after treatment with interferon-alpha.
    Reiter A; Marley SB; Hochhaus A; Sohal J; Raanani P; Hehlmann R; Gordon MY; Goldman JM; Cross NC
    Br J Haematol; 1998 Sep; 102(5):1271-8. PubMed ID: 9753056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic impact of interferon alpha-induced cytogenetic remission in chronic myelogenous leukaemia: long-term follow-up.
    Kloke O; Niederle N; Opalka B; Hawig I; Seeber S; Becher R
    Eur J Haematol; 1996; 56(1-2):78-81. PubMed ID: 8599999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An extremely delayed cytogenetic response to interferon-alpha in a patient with chronic myeloid leukaemia.
    Whiteway AJ; Reid CD; Cross NC
    Leukemia; 1997 Apr; 11(4):614-6. PubMed ID: 9096705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders.
    Bonifazi F; de Vivo A; Rosti G; Guilhot F; Guilhot J; Trabacchi E; Hehlmann R; Hochhaus A; Shepherd PC; Steegmann JL; Kluin-Nelemans HC; Thaler J; Simonsson B; Louwagie A; Reiffers J; Mahon FX; Montefusco E; Alimena G; Hasford J; Richards S; Saglio G; Testoni N; Martinelli G; Tura S; Baccarani M; ; ; ; ; ; ; ;
    Blood; 2001 Nov; 98(10):3074-81. PubMed ID: 11698293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Chronic myelogenous leukemia].
    Urabe A
    Nihon Rinsho; 2006 Jul; 64(7):1286-90. PubMed ID: 16838646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recombinant alpha-interferon as treatment for chronic myelogenous leukemia in relapse after allogeneic bone marrow transplantation: a report from the Société Française de Greffe de Moelle.
    Pigneux A; Devergie A; Pochitaloff M; Rio B; Archimbaud E; Cahn JY; Leblond V; Michallet M; Jouet JP; Guilhot F
    Bone Marrow Transplant; 1995 Jun; 15(6):819-24. PubMed ID: 7581075
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interferon-alpha therapy for chronic myelogenous leukemia.
    Wetzler M; Kantarjian H; Kurzrock R; Talpaz M
    Am J Med; 1995 Oct; 99(4):402-11. PubMed ID: 7573097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Initial treatment of chronic myelogenous leukemia--interferon or bone marrow transplantation].
    Urabe A
    Gan To Kagaku Ryoho; 1999 Sep; 26(10):1381-6. PubMed ID: 10500523
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.